Phase Code: SCF-CF-AEROVIA201-EBP-P7-0001
Objective: Model resistance, compensatory biology, host-defense preservation, off-target risks, and chronic-use safety for inhaled AEROVIA-201.
7.1 Core Safety Hypothesis
AEROVIA-201 must reduce excessive neutrophil elastase activity without eliminating protective innate immune protease function.
Therapeutic window objective:
Partial, localized pulmonary modulation rather than systemic or complete elastase blockade.
7.2 Resistance & Adaptation Risk Map
Risk Domain | Potential Failure Mode | Monitoring Strategy |
Protease compensation | Proteinase 3 or cathepsin G upregulation | Protease panel assay |
Infection susceptibility | Reduced bacterial clearance | Pathogen burden and killing assays |
Biofilm persistence | Biofilm adapts despite reduced tissue injury | Biofilm density and antibiotic synergy assays |
Cytokine rebound | IL-8/TNF rise after dosing | Longitudinal cytokine panel |
ECM repair impairment | Excess suppression delays remodeling | Collagen/elastin turnover markers |
Microbiome disruption | Shifts in airway ecology | Sputum microbiome sequencing |
7.3 Host-Defense Preservation Model
Host-Defense Function | Safety Requirement |
Neutrophil recruitment | Preserve baseline response |
Bacterial killing | No meaningful reduction |
Macrophage activity | No suppressive effect |
Mucociliary clearance | No worsening |
Epithelial barrier repair | Preserve or improve |
Antimicrobial peptide activity | No suppression |
7.4 Off-Target Safety Panel
Off-Target Class | Required Evaluation |
Related serine proteases | Proteinase 3, cathepsin G, trypsin, chymotrypsin |
Coagulation proteases | Screening if systemic exposure is measurable |
Matrix proteases | MMP panel monitoring |
Ion channels | Airway epithelial electrophysiology |
CYP enzymes | Basic metabolic liability screen |
hERG | Required if systemic exposure is non-negligible |
7.5 Pulmonary Safety Modeling
Safety Endpoint | Acceptance Target |
Bronchoreactivity | No clinically meaningful increase |
Airway irritation | Minimal |
BAL inflammatory cells | No pathological increase |
Epithelial cytotoxicity | Low/no cytotoxicity |
Ciliary function | Preserved |
Surfactant compatibility | No disruptive interaction |
7.6 Chronic-Use Risk Assessment
Chronic Risk | Mitigation |
Over-inhibition of elastase | Dose ceiling and partial-modulator design |
Reduced pathogen clearance | Infection monitoring and exclusion thresholds |
Tissue repair interference | ECM turnover biomarker monitoring |
Systemic leakage | High lung/plasma ratio requirement |
Accumulation | Repeat-dose PK monitoring |
Immunologic drift | Cytokine and cell-profile surveillance |
7.7 Combination Safety Model
AEROVIA-201 is expected to be used with CFTR modulators and standard CF care.
Combination Partner | Safety Question |
CFTR modulators | No PK/PD interference |
Inhaled antibiotics | No antagonism; possible synergy |
Mucolytics | Formulation compatibility |
Hypertonic saline | Airway tolerability |
Pancreatic enzymes | No direct interaction expected |
Anti-inflammatory agents | Avoid cumulative immune suppression |
7.8 SCF PCR Safety Positioning
PCR Layer | Safety Role |
Preventative | Prevent protease-driven structural drift |
Curative | Reduce active inflammatory tissue injury |
Restorative | Support ECM preservation without blocking repair |
7.9 Preclinical Safety Gate
Gate | Required Result |
Protease selectivity | Favorable |
Epithelial tolerability | Pass |
Host-defense preservation | Pass |
Pulmonary PK safety | Pass |
Repeat-dose tolerability | Pass |
Combination compatibility | Pass |
7.10 Phase 7 Decision
Safety model outcome:
AEROVIA-201 remains viable if developed as a localized, partial neutrophil elastase modulator with strict host-defense and pulmonary tolerability gates.
Decision:
PROCEED TO PHASE 8 — TRANSLATIONAL BLUEPRINTING
MASTER REGISTRY INDEX
SCF-CF-AEROVIA201-EBP-P7-0001 — Resistance Prevention & Safety Modeling
SCF-CF-API-201 — AEROVIA-201 Pulmonary Neutrophil Elastase Modulator
SCF-SAFETY-0001 — SCF Safety Harmonization Framework
SCF-PKPD-0001 — Pharmacokinetic & Pharmacodynamic Framework
SCF-PCR-0001 — Preventative–Curative–Restorative Architecture
SCF-ETHBIO-WF-0001 — SCF Ethnobioprospecting Workflow